作者:Marta Rejmund、Anna Mrozek-Wilczkiewicz、Katarzyna Malarz、Monika Pyrkosz-Bulska、Kamila Gajcy、Mieczyslaw Sajewicz、Robert Musiol、Jaroslaw Polanski
DOI:10.1371/journal.pone.0188767
日期:——
A new class of TSCs containing piperazine (piperazinylogs) of Triapine, was designed to fulfill the di-substitution pattern at the TSCs N4 position, which is a crucial prerequisite for the high activity of the previously obtained TSC compounds–DpC and Dp44mT. We tested the important physicochemical characteristics of the novel compounds L1-L12. The studied ligands are neutral at physiological pH, which allows them to permeate cell membranes and bind cellular Fe pools more readily than less lipid-soluble ligands, e.g. DFO. The selectivity and anti-cancer activity of the novel TSCs were examined in a variety of cancer cell types. In general, the novel compounds demonstrated the greatest promise as anti-cancer agents with both a potent and selective anti-proliferative activity. We investigated the mechanism of action more deeply, and revealed that studied compounds inhibit the cell cycle (G1/S phase). Additionally we detected apoptosis, which is dependent on cell line’s specific genetic profile. Accordingly, structure-activity relationship studies suggest that the combination of the piperazine ring with Triapine allows potent and selective anticancer chelators that warrant further in vivo examination to be identified. Significantly, this study proved the importance of the di-substitution pattern of the amine N4 function.
设计了一类包含哌嗪的Triapine(哌嗪类似物)作为靶向铁硫簇(TSCs)的新一类化合物,旨在实现TSCs的N4位置上的二取代模式,这是先前获得的具有高活性的TSC化合物–DpC和Dp44mT的关键前提。我们测试了新型化合物L1-L12的重要物理化学特性。这些配体在生理pH下呈中性,这使得它们比亲脂性较低的配体(如DFO)更容易穿透细胞膜并结合细胞内的铁库。在多种癌细胞类型中检测了这些新型TSCs的选择性和抗癌活性。总体而言,这些新型化合物展现出最有希望作为抗癌剂,具有强效且选择性的抗增殖活性。我们更深入地研究了这些化合物的作用机制,发现它们能够抑制细胞周期(G1/S期)。此外,我们还检测到了依赖于细胞系特定遗传背景的凋亡现象。因此,构效关系研究表明,哌嗪环与Triapine的结合使得能够识别出具有强效且选择性的抗癌螯合剂,这些螯合剂值得进一步进行体内研究。值得注意的是,这项研究证明了胺N4功能的二取代模式的重要性。